Epigenetics in Cardiovascular Disease, a new volume in the Translational Epigenetics series, offers a comprehensive overview of the epigenetics mechanisms governing cardiovascular disease development, as well as instructions in research methods and guidance in pursing new studies. More than thirty international experts provide an (i) overview of the epigenetics mechanisms and their contribution to cardiovascular disease development, (i) high-throughput methods for RNA profiling including single-cell RNA-seq, (iii) the role of nucleic acid methylation in cardiovascular disease development, (iv) epigenetic actors as biomarkers and drug targets, (v) and the potential of epigenetics to advance personalized medicine. Here, readers will discover strategies to combat research challenges, improve quality of their epigenetic research and reproducibility of their findings. Additionally, discussion of assay and drug development for personalized healthcare pave the way for a new era of understanding in cardiovascular disease.
- Offers a thorough overview of role of epigenetics mechanisms in cardiovascular disease
- Includes guidance to improve research plans, experimental protocols design, quality and reproducibility of results in new epigenetics research
- Explores biomarkers and drug targets of therapeutic potential to advance personalized healthcare
- Features chapter contributions from a wide range of international researchers in the field
SECTION I INTRODUCTORY INFORMATION
1. The ever-growing burden of cardiovascular disease
2. Epigenetics concepts: An overview
3. From classical signaling pathways to the nucleus
SECTION II EPIGENETICS MECHANISMS IN CARDIOVASCULAR DISEASE
4. DNA methylation in heart failure
5. Histone modifications in cardiovascular disease initiation and
progression
6. RNA modifications in cardiovascular diseaseAn experimental and
computational perspective
7. Regulatory RNAs in cardiovascular disease
8. Regulation of splicing in cardiovascular disease
9. Cardiac transcriptomic remodeling in metabolic syndrome
10. Sex differences in epigenetics mechanisms of cardiovascular disease
11. Epigenetics in cardiac development and human induced pluripotent stem
cells
SECTION III BIOMARKER VALUE
12. Peripheral blood DNA and RNA biomarkers of cardiovascular disease in
clinical practice
13. Epigenetics and physical exercise
14. Long noncoding RNAs and circular RNAs as heart failure biomarkers
15. Artificial intelligence in clinical decision-making for diagnosis of
cardiovascular disease using epigenetics mechanisms
SECTION IV THERAPEUTIC POTENTIAL
16. Therapeutic strategies for modulating epigenetic mechanisms in
cardiovascular disease
SECTION V METHODOLOGICAL ISSUES
17. Single-cell RNA sequencing in cardiovascular science
18. Good laboratory and experimental practices for microRNA analysis in
cardiovascular research
19. Analytical challenges in microRNA biomarker development: Best practices
for analyzing microRNAs in cell-free biofluids
20. Concept of biological reference materials for RNA analysis in
cardiovascular disease
21. Unbiased bioinformatics analysis of microRNA transcriptomics datasets and
network theoretic target prediction
Dr Devaux is Chairing the EU-CardioRNA COST Action, an international network of 30 European countries focusing on Transcriptomics in Cardiovascular Disease. Dr Robinson is leading a Working Group on Dissemination activities in the Action. The network, with 100+ individual experts in the field of Epigenetics in cardiovascular disease, constitutes an invaluable reservoir of co-authors for the Volume.
Biežāk uzdotie jautājumi par e-grāmatām